People · Operator
Named in public records as an officer, director or promoter · active 2009–2013 · Pharmaceuticals
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Inspyr Therapeutics, Inc. | — | Pharmaceuticals | Series A | $25.6M | $12.1M | 2009 |
| Aeolus Pharmaceuticals, Inc. | — | Pharmaceuticals | Series A | $18.5M | $209.0M | 2009 |
| Melior Discovery, Inc | — | Pharmaceuticals | Seed | $2.8M | $66.3M | 2013 |
JOHN FARAH at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside JOHN FARAH on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Michael Lewis | 1 | 12 |
| Amit Kumar | 1 | 8 |
| Robert Adelson | 1 | 5 |
| Scott Ogilvie | 1 | 4 |
| Michael E Lewis | 1 | 4 |
| Chris A. Rallis | 1 | 3 |
| Robert S. Adelson | 1 | 3 |
| Brian Day | 1 | 3 |
| Andrew Reaume | 1 | 2 |
| Michael Cain | 1 | 2 |
| Joseph J. Krivulka | 1 | 2 |
| Toby Moskovits | 1 | 2 |
| Peter Suzdak | 1 | 2 |
| Jeffrey A. Scott | 1 | 2 |
| David Cavalier | 1 | 2 |
| JOHN McMANUS | 1 | 2 |
| Bo Jesper Hansen | 1 | 2 |
| Russell Skibsted | 1 | 2 |
| Chris Rallis | 1 | 2 |
| Bobba Venkatadri | 1 | 2 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.